Mark Schoenberg - 28 Jul 2025 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Medical Officer
Signature
/s/ Jason D. Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
28 Jul 2025
Net transactions value
-$98,552
Form type
4
Filing time
30 Jul 2025, 16:02:05 UTC
Previous filing
11 Jun 2025
Next filing
13 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Schoenberg Mark Chief Medical Officer 400 ALEXANDER PARK DRIVE, PRINCETON /s/ Jason D. Smith, Attorney-in-Fact 30 Jul 2025 0001763581

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +10,000 +6.5% 163,378 28 Jul 2025 Direct F1, F2
transaction URGN Ordinary Shares Sale $98,552 -5,149 -3.2% $19.14 158,229 28 Jul 2025 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the settlement of performance stock units granted on January 31, 2024 that vested upon the achievement of a corporate milestone event.
F2 Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer.
F3 Represents shares sold to satisfy withholding tax obligations upon the settlement of performance stock units.